2015 American Transplant Congress
Induction Therapy (IT) in Simultaneous Pancreas and Kidney Transplantation (SPK) according to Patient Risk – A Registry Analysis
Purpose: Optimal IT in SPK recipients (rec) according to patient risk has not been studied.Methods: Using the International Pancreas Transplant Registry database, we analyzed IT…2015 American Transplant Congress
Immunosuppression and Reoperation After Simultaneous Kidney Pancreas Transplantation Convey Greatest Risk for Rejection
Background: Episodes of acute cellular rejection (ACR) convey significant morbidity after simultaneous kidney and pancreas transplantation (SPK). The role of recipient sensitization, immunosuppression (IS) and…2015 American Transplant Congress
Can Post-Transplant C-Peptide Be Used as an Indicator of Pancreas Graft Failure?
Background: The OPTN Pancreas Transplantation Committee is attempting to define pancreas graft failure and performed a study to determine if C-peptide corresponds to pancreas graft…2015 American Transplant Congress
Pancreas Transplantation Immunosuppression Induction With Rabbit Antithymocyte Globulin +/- Rituximab and Early Steroid Withdrawal: Experience With >500 Recipients
T-cell depleting antibody induction, often combined with steroid withdrawal, has become standard practice for pancreas transplantation. In this study, outcomes of >500 pancreas transplants using…2015 American Transplant Congress
Outcomes of Simultaneous Pancreas and Kidney Transplantation With a High Level of Preformed Antibodies
Transplant Surgery, Manchester Royal Infirmary, Manchester, United Kingdom.
BACKGROUND:There is paucity of data of outcomes of simultaneous pancreas and kidney transplantation in recipients with preformed antibodies. Newer induction agents have been used with…2015 American Transplant Congress
Long-Term Metabolic Outcomes of Functioning Pancreas Transplants in Type 2 Diabetic Recipients
Asan Medical Center, Seoul, Korea.
Background Limited data are available on long-term metabolic outcomes of functioning pancreas transplants in patients with type 2 diabetes mellitus (T2DM). The aim of this…2015 American Transplant Congress
Optimal Induction Therapy (IT) in Pancreas After Kidney Transplantation (PAK) According to Type of Kidney (kd) Donor and Patient Risk – A Registry Analysis
1University of Arizona, Tucson, AZ; 2University of Arizona, Tucson, AZ.
Purpose: Best IT in PAK recipients (rec) according to type of kd donor (LD vs. DD) and rec risk has not been determined.Methods: Using the…2015 American Transplant Congress
Safety and Efficacy of Conversion from Conventional Twice Daily Tacrolimus to Once Daily Extended Release Tacrolimus in Stable Pancreas Transplant (SPK and PAK) Recipients
Surgery, Multi-Organ Transplant, Toronto General Hospital, Toronto, ON, Canada.
Background: A once-daily, modified-release oral formulation of tacrolimus has been developed to simplify dosing and improve medication adherence. There is limited data on the implementation…2015 American Transplant Congress
Post-Donation Outcomes in 46 Live Pancreas Donors
Division of Transplantation, Department of Surgery, University of Minnesota, Minneapolis, MN.
Background: Live donor segmental pancreas transplants have been performed selectively to increase the pool of donors, minimize cold ischemia time, and to avoid brain death.…2015 American Transplant Congress
Long Term Follow Up Reveals Satisfactory Renal Outcome in Pacreas After Kidney Transplantation (PAK)
Objective: PAK offers diabetic ESRD patients' opportunity to avoid or minimize dialysis using living kidney donation, followed by cadaveric pancreas transplantation thereafter to restore euglycemia,…
American Transplant Congress abstracts